A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2

Neurology

Volumn 75, Issue 13, 2010, Pages 1189-1194

  Kay, D M ^a   Stevens, C F ^a   Hamza, T H ^a   Montimurro, J S ^a   Zabetian, C P ^b,c   Factor, S A ^d,e   Samii, A ^c   Griffith, A ^f   Roberts, J W ^g   Molho, E S ^e   Higgins, D S ^e,h   Gancher, S ^b   Moses, L ^a   Zareparsi, S ^j   Poorkaj, P ^b   Bird, T ^b,i   Nutt, J ^k   Schellenberg, G D ^b,l   Payami, H ^a  

^a WADSWORTH CENTER   (United States)

^b Department of Geriatric ^*  (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f Evergreen Hospital Medical Center   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h STRATTON VA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j WEST VIRGINIA UNIVERSITY   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; PROTEIN PARK2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; PARKIN;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COFFEE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MULTIPLICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; ONSET AGE; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; AGE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; REFERENCE VALUE;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REFERENCE VALUES; SEQUENCE DELETION; STATISTICS, NONPARAMETRIC; UBIQUITIN-PROTEIN LIGASES;

EID: 77957968209     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f4d832     Document Type: Article

References (32)

1. Asakawa S, Tsunematsu K, Takayanagi A, et al. The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 2001;286:863-868.
2. Cesari R, Martin ES, Calin GA, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003;100:5956-5961.
3. Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblas-toma and other human malignancies. Nat Genet 2010;42: 77-82.
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinson-ism. Nature 1998;392:605-608.
5. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004;427:636-640.
6. Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009;459:569-573.
7. Wongseree W, Assawamakin A, Piroonratana T, Sinsom-ros S, Limwongse C, Chaiyaratana N. Detecting purely epistatic multi-locus interactions by an omnibus permutation test on ensembles of two-locus analyses. BMC Bioin-formatics 2009;10:294.
8. Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE. Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet 2009;18:3206-3216.
9. Chien HF, Rohe CF, Costa MD, et al. Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil. Neurogenetics 2006;7:13-19.
10. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002;58:1239-1246.
11. Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet 2008;45:43-46.
12. Clark LN, Afridi S, Karlins E, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol 2006;63:548-552.
13. Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003;60:796-801.
14. Pankratz N, Kissell DK, Pauciulo MW, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009; 73:279-286.
15. Sun M, Latourelle JC, Wooten GF, et al. Influence of het-erozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006; 63:826-832.
16. Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 2003;53:624-629.
17. Schlitter AM, Kurz M, Larsen JP, et al. Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. Acta Neurol Scand 2006;113:9-13.
18. Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005;64:134-136.
19. Mortiboys H, Thomas KJ, Koopman WJ, et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008;64:555-565.
20. Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 2003;18:1306-1311.
21. Bruggemann N, Mitterer M, Lanthaler AJ, et al. Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. Parkinsonism Relat Disord 2009;15: 425-429.
22. Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007;61:47-54.
23. Gibb W, Lees A. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
24. Poorkaj P, Nutt JG, James D, et al. Parkin mutation analysis in clinic patients with early-onset Parkinson's disease. Am J Med Genet A 2004;129:44-50.
25. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene: French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
26. Djarmati A, Guzvic M, Grunewald A, et al. Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. Mov Disord 2007;22:1708-1714.
27. Scarciolla O, Brancati F, Valente EM, et al. Multiplex ligation-dependent probe amplification assay for simultaneous detection of Parkinson's disease gene rearrangements. Mov Disord 2007;22:2274-2278.
28. Powers K, Kay D, Factor S, et al. Combined effects of smoking, coffee and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88-95.
29. Kay DM, Factor SA, Samii A, et al. Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1222-1230.
30. Mata I, Samii A, Factor S, et al. Variation in the 3' region of the alpha-synuclein gene modifies risk for Parkinson's disease. Mov Disord 2009;24:S145.
31. Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 2007;62:137-144. Available at: http://www.pdgene.org/. Accessed November 29, 2009.
32. Payami H, Kay DM, Zabetian CP, Schellenberg GD, Factor SA, McCulloch CC. Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. Genet Epidemiol 2009;34:92-99.